Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response

Heart. 2004 Jan;90(1):13-6. doi: 10.1136/heart.90.1.13.


Intrauterine and neonatal manifestations of congenital long QT syndrome are associated with a high cardiac risk, particularly when atrioventricular block and excessive QT prolongation (> 600 ms(1/2)) are present. In a female newborn with these features, treatment with propranolol and mexiletine led to complete reduction of arrhythmia that was maintained 1.5 years later. High throughput genetic analysis found a sodium channel gene (LQT3) mutation. Disappearance of the 2:1 atrioventricular block and QTc shortening (from 740 ms(1/2) to 480 ms(1/2)), however, was achieved when mexiletine was added to propranolol. This effect was considered to be possibly genotype related. Early onset forms of long QT syndrome may benefit from advanced genotyping.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Electrocardiography
  • Female
  • Genotype
  • Humans
  • Infant, Newborn
  • Long QT Syndrome / congenital*
  • Long QT Syndrome / diagnosis
  • Long QT Syndrome / therapy
  • Mutation / genetics
  • Pedigree
  • Phenotype
  • Treatment Outcome